Trial with the ATR Inhibitor BAY-1895344 in Patients with advanced solid Tumors and Lymphomas (first use in humans)

SAKK 69/17

Coordinating investigator

Prof. Dr. med.
Markus
Jörger
Kantonsspital St. Gallen
+41 76 559 10 70

With this trial we would like to evaluate the safety and tolerability of the trial medication BAY-1895344 in patients with advanced cancer (solid malignant tumors and Non-Hodgkin’s-lymphoma).

The trial medication is being tested on humans for the first time. In doing so, we want to find out the highest dose that can be safely administered. In addition, we want to observe how the trial medication changes and distributes in the body and how the treated cancer disease responds to this therapy. 

The trial medication blocks an enzyme called ATR kinase, which is part of the ATR metabolic pathway. The ATR pathway is often relied upon in cancer cells so that they can survive and grow. There is therefore reason to believe that inhibiting the ATR pathway could reduce cancer cells growth.

Patients, who are suffering from a malignant solid tumor or Non-Hodgkin’s-lymphoma and where standard treatments are no longer working, can participate. 222 patients worldwide will take part in this clinical trial. The trial, resp. the intake of the trial medication will continue until it no longer brings benefit or the patient's health worsens.

 

Trial Country Leader
PD Dr. med. M. Jörger, Kantonsspital St. Gallen, +41 76 559 10 70

Further Informationen
More trial information can be found at www.ClinicalTrials.gov.

Clinics

All trials